BIOFIT2019 – very successful Business convention and Congress #BIOFIT2019 Despite the strike, BIOFIT2019 in Marseille was a very successful edition with more than 1150 delegates, 13 000 meetings at the business convention, companies from 35 countries, 16 conferences, 4 hosted Events, 120 exhibitors. This event give the opportunity for start-ups, mature companies and pharma to meet […]

  Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com   SPECIAL REPORT #45     2019 Major Pivotal Clinical Trials Failures     Pivotal Phase 3 clinical trials are of utmost importance for the registration and the launch of a new drug, a new indication or of a combination of drugs for the treatment of […]

  Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #44     Sanofi Capital Markets Day       Precisely one hundred days after taking office, Paul Hudson, Sanofi’s new CEO has disclosed, at a Capital Markets Day meeting held in Cambridge, (MA, USA), on December 10, details of the strategy […]

Btobioinnovation.com   Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com   SPECIAL REPORT #43     Novartis R&D Day       On Thursday December 5, Novartis, the largest European Biopharmaceutical company, with 2019 expected sales nearing $55 billion, has detailed its development efforts during its annual R&D Day, in London. In terms of approval 2019 […]

Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com       SPECIAL REPORT #42     The Top 10 Biopharmaceutical recent M&A Failures       Earlier this week Fierce Pharma has reported fifteen M&A deals that were considered as major failures. We have picked ten of them, which ranged from $63 billion to $8 billion […]